证券代码：002461 证券简称：珠江啤酒 公告编号：2025-016 二、股权登记日与除权除息日 本次权益分派股权登记日为：2025 年 6 月 11 日，除权除息日为：2025 年 6 月 12 日。 广州珠江啤酒股份有限公司 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 广州珠江啤酒股份有限公司（以下简称"公司"或"本公司"）2024 年 年度权益分派方案已获 2025 年 4 月 23 日召开的 2024 年度股东大会审议通 过，本次实施的分配方案与 2024 年度股东大会审议通过的分配方案及其调整 原则一致，将按分配总额固定的原则实施，自分配方案披露至实施期间公司 总股本未发生变化，本次实施分配方案时间距离 2024 年度股东大会审议通过 之日未超过两个月。现将权益分派事宜公告如下： 一、权益分派方案 本公司 2024 年年度权益分派方案披露至实施期间公司股本总额无变化， 经股东大会审议通过的分配方案为：以公司现有总股本 2,213,328,480 股为 基数，向全体股东每 10 股派 1.700000 元人民币现金（含税；扣税后，通过 深股通持有股份的 ...

目 录 上海灿瑞科技股份有限公司 2024 年年度股东大会会议资料 上海灿瑞科技股份有限公司 二〇二五年六月 上海灿瑞科技股份有限公司 会议资料 上海灿瑞科技股份有限公司 2024 年年度股东大会会议资料 为维护全体股东的合法权益，确保本次股东大会的正常秩序和议事效率，保 证大会的顺利召开，根据《中华人民共和国公司法》、 《上市公司股东大会规则》、 《公司章程》以及《上海灿瑞科技股份有限公司股东大会议事规则》的有关规定， 特制定会议须知如下： 一、大会设秘书处，负责会议的组织工作和处理相关事宜。 二、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 三、请出席大会的股东或其代理人或其他出席者在会议召开前30分钟到达会 场办理签到手续，并请按规定出示证券账户卡、身份证、法定代表人/执行事务 合伙人委派代表身份证明书、营业执照复印件（加盖公章）、授权委托书等证明 文件，经验证后方可出席会议。为保证本次大会的严肃性和正常秩序，切实维护 股东的合法权益，务必请出席大会的股东或其代理人或其他出席者准时到达会场 签到确认参会资格，在会议主持人 ...

证券代码：688449 证券简称：联芸科技 公告编号：2025-021 联芸科技（杭州）股份有限公司 关于全资子公司开立募集资金专项账户 并签订募集资金专户存储三方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意联芸科技（杭州）股份有限公司首次 公开发行股票注册的批复》（证监许可2024906 号）核准，联芸科技 2024 年 11 月 29 日 于 上 海 证 券 交 易 所 以 每 股 人 民 币 11.25 元 的 发 行 价 格 公 开 发 行 保荐及承销费共计人民币 58,875,000.00 元后，公司实际收到上述 A 股的募集资 金人民币 1,066,125,000.00 元，扣除由公司支付的其他发行费用后，实际募集资 金净额为人民币 1,033,365,759.76 元。上述募集资金于 2024 年 11 月 22 日全部到 账，并经德勤华永会计师事务所（特殊普通合伙）验证并出具德师报（验）字（24） 第 00198 号验资报告。上述募 ...

Core Viewpoint - The candidate Zhang Huiming has declared his qualifications and independence to serve as an independent director for Shanghai Jin Jiang International Hotel Co., Ltd, ensuring compliance with relevant laws and regulations [1][4]. Summary by Sections Qualifications - The candidate possesses basic knowledge of listed company operations and has over 5 years of relevant work experience in law, economics, accounting, finance, or management [1]. - The candidate has completed training and obtained certification recognized by the stock exchange [1]. Independence - The candidate confirms independence by not being involved in any of the specified relationships or situations that could compromise independence, such as holding significant shares or being employed by related entities [2][3]. - The candidate has no adverse records, including administrative or criminal penalties from the China Securities Regulatory Commission (CSRC) in the last 36 months [3]. Commitment - The candidate has undergone qualification verification by the nomination committee of the board and has no conflicts of interest with the nominating entity [3][4]. - The candidate commits to fulfilling the responsibilities of an independent director, adhering to laws and regulations, and ensuring independent judgment without influence from the company or its major shareholders [4].

金凯生科：股东启鹭投资和青松投资拟合计减持不超过4%公司股份 智通财经6月4日电，金凯生科(301509.SZ)公告称，股东启鹭投资计划减持不超过3%公司股份，其中通 过集中竞价方式减持不超过1%，通过大宗交易方式减持不超过2%。青松投资计划通过集中竞价方式减 持不超过1%公司股份。减持期间为自公告之日起十五个交易日后的三个月内。 ...

Core Viewpoint - The beauty brand Proya is entering the medical aesthetics market with its first medical device product, a collagen patch aimed at post-surgery recovery, as it seeks new growth avenues amid slowing growth of its main brand [1][3][5]. Company Summary - Proya has launched its first medical device product, the medical collagen patch, which is designed for post-surgery skin care [1][3]. - The product is priced at 163 yuan after discount, down from 198 yuan, and is targeted at various skin recovery scenarios [3]. - Proya's main brand revenue growth is slowing, with a reported revenue of 85.81 billion yuan in 2024, showing less than 20% growth compared to previous years [5][6]. - The company aims to achieve a revenue scale exceeding 100 billion yuan in 2024 and has set a goal to enter the top ten global cosmetics companies within the next decade [6][9]. Industry Summary - The medical aesthetics market in China is rapidly expanding, with a market size of approximately 266.9 billion yuan in 2023, projected to exceed 700 billion yuan by 2031 [3][4]. - Other domestic beauty brands, such as Shanghai Jahwa and Beitaini, are also entering the medical aesthetics space, indicating a competitive landscape [4]. - The medical aesthetics sector is still in a phase of complete competition, with no dominant brands yet established, presenting opportunities for new entrants like Proya [4][9]. - Proya's entry into the medical aesthetics market is seen as a necessary strategy to maintain growth and compete with international brands, which have stronger brand positioning and marketing capabilities [9].

从业务层面来看，本次交易涉及的标的资产经营范围多为生猪养殖及销售、畜牧养殖技术开发及技术服 务、农作物种植及销售等，与邦基科技主营的饲料业务有较强协同性。 近年来，饲料行业逐步从规模扩张向提质增效转型，市场竞争的深度、广度、激烈程度均有所提升，行 业整合趋势明显。一方面，大型饲料企业通过产业联盟、收购兼并等方式延伸产业链布局，正逐步转化 为产业链整合者。另一方面，由于养殖业行情变化，以商品饲料生产为主的企业逐渐渗透至下游养殖 业，部分产能转为自用。 6月4日晚间，邦基科技（603151）发布公告称，正在筹划以发行股份及支付现金相结合的方式，购买 Riverstone Farm Pte.Ltd.所持有的山东北溪农牧有限公司、山东瑞东伟力农牧有限公司、山东鑫牧农牧 科技有限公司、瑞东农牧(利津)有限公司、瑞东农牧(山东)有限责任公司、瑞东威力牧业(滨州)有限公司 100%股权以及派斯东畜牧技术咨询(上海)有限公司80%股权。 结合前述行业背景，本次邦基科技并购山东北溪农牧有限公司等企业，有望整合产业链资源，延伸产业 链条，在技术、市场等方面发挥协同效应。 目前，邦基科技已经与交易对方达成初步意向，具体方案及条款将 ...

Core Viewpoint - The acquisition of Wuhan Jabil by Guangku Technology aims to enhance its product line and market position in the optical components sector, leveraging Jabil's existing capabilities and customer resources [1][2]. Group 1: Acquisition Details - Guangku Technology announced the acquisition of Wuhan Jabil for a total consideration of $17 million plus adjustments based on the company's net cash and transaction costs at closing [1][2]. - The acquisition will result in Guangku Technology holding 100% of Wuhan Jabil, making it the sole shareholder [1]. Group 2: Financial Performance - Wuhan Jabil reported a revenue of 241 million yuan and a net profit of 6.5164 million yuan in 2024, with a total asset value of 294 million yuan at the end of the first quarter [1]. - JBL, the parent company of Wuhan Jabil, experienced a significant decline in net profit, reporting approximately $200 million, down 80% year-on-year [1]. Group 3: Strategic Benefits - The acquisition is expected to optimize Guangku Technology's customer structure, enrich its product line, and expand production scale, thereby enhancing overall competitiveness [2]. - Guangku Technology's products are widely used in core areas of the optical fiber laser, optical fiber communication, and data center industries, with a total revenue of 999 million yuan in the previous year, reflecting a year-on-year growth of approximately 40% [2]. Group 4: Future Development Plans - Guangku Technology plans to focus on the development of optical fiber laser devices, optical communication devices, lithium niobate modulators, and photonic integrated devices [3]. - The company aims to enhance its integrated multifunctional component offerings and expand into the laser radar integration module market, particularly with 1550nm emitting light source modules [3]. - In 2024, Guangku Technology increased its R&D investment in high-speed lithium niobate modulator chips and laser radar light source modules, with R&D expenses reaching 141.49 million yuan, a year-on-year increase of 14.19% [3].

金凯生科（301509）公告，股东启鹭投资计划减持不超过361.2万股，占公司总股本3%。其中，通过集 中竞价方式减持不超过120.4万股，占公司总股本1%；通过大宗交易方式减持不超过240.8万股，占公司 总股本2%。股东青松投资计划通过集中竞价方式减持不超过120.4万股，占公司总股本1%。减持期间为 自公告之日起十五个交易日后的三个月内。 ...